Patents

US 11833164 B2: Methods of treating Fabry disease in patients having a mutation in the GLA gene

Granted
2023-12-05
Filed
2020-08-07 application 16987884
Type
Utility · 33 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing α-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for α-galactosidase A, wherein the patient has a mutation in the nucleic acid sequence encoding α-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.

Source: PVGPATDIS, file of 2026-04-10 (ipg231205.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
Amicus Therapeutics, Inc. 158 patentsUS company or organizationPhiladelphia, PAAMICUS THERAPEUTICS, INC. Form D issuer EXACT high confidence: identical full name and state
AMICUS THERAPEUTICS, INC. SEC filer EXACT medium confidence: identical full name, one of each nationally
PVGPATDIS, file of 2026-04-10

Inventors

InventorPlacePatentsPerson pageSource
Elfrida BenjaminMillstone Township, NJ57PVGPATDIS, file of 2026-04-10
Xiaoyang WuEdison, NJ21PVGPATDIS, file of 2026-04-10

CPC categories

SubclassCategoryFirst groupSource
A61KPreparations for medical, dental or toiletry purposesA61K31/7008PVGPATDIS, file of 2026-04-10
G16BBioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biologyG16B20/00PVGPATDIS, file of 2026-04-10
A61PSpecific therapeutic activity of chemical compounds or medicinal preparationsA61P3/00PVGPATDIS, file of 2026-04-10
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms ; compositions or test papers therefor; processes of preparing such compositions; condition-responsive control in microbiological or enzymological processesC12Q1/6883PVGPATDIS, file of 2026-04-10
C12YEnzymesC12Y302/01022PVGPATDIS, file of 2026-04-10
G16HHealthcare informatics, i.e. information and communication technology [ict] specially adapted for the handling or processing of medical or healthcare dataG16H50/20PVGPATDIS, file of 2026-04-10

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2026-04-27Release of security interest
Release of security interest
WILMINGTON TRUST, NATIONAL ASSOCIATION signed 2026-04-27AMICUS THERAPEUTICS, INC. PHILADELPHIA, PA75494/30PASDL, file of 2026-08-13
2026-04-27Security interest Security interest
Security interest
BIOMARIN PHARMACEUTICAL INC. signed 2026-04-27
AMICUS THERAPEUTICS, INC. signed 2026-04-27
CITIBANK, N.A., AS COLLATERAL AGENT NEW YORK, NY75493/968PASDL, file of 2026-10-15
2023-10-19Assignment
Assignment of assignor's interest
BENJAMIN, ELFRIDA signed 2023-10-18
WU, XIAOYANG signed 2023-10-18
AMICUS THERAPEUTICS, INC. PHILADELPHIA, PA65277/426PASDL, file of 2026-08-13
2023-10-06Security interest Security interest
Security interest
AMICUS THERAPEUTICS, INC. signed 2023-10-05WILMINGTON TRUST, NATIONAL ASSOCIATION MINNEAPOLIS, MN65177/196PASDL, file of 2026-10-15

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.